1. Medtech Insight
  2. >>Business
  3. >>R&D

Trial Shows InSightec's Tremor Therapy Could Improve With Better Imaging

 
• By Reed Miller

Results of a small clinical trial of tractography-based ventral intermediate nucleus-targeting suggest this MRI-based imaging approach could help improve the outcomes of focused ultrasound brain intervention with InSightec's Exablate Neuro system for the noninvasive treatment of essential tremor.

A novel approach to magnetic resonance imaging of the brain could make InSightec Ltd.'s Exablate Neuro focused ultrasound system more effective and safer for the treatment of neurological disorders, according to results of a small feasibility trial.

Essential tremor is a unique neurological condition caused by a deficiency of a brain chemical called gamma-aminobutyric acid (GABA) or...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Business

FDA Document Request Denied As Case Against SurModics Merger Intensifies

 
• By Elizabeth Orr

A federal court in Illinois ruled against SurModics and BC Holdings' request for FDA documents to support a proposed merger. The FTC has challenged the merger, claiming it threatens competition in hydrophilic device coatings. The ruling may indicate the FTC is likely to succeed.

Abbott Lowers Outlook But Headwinds Are Temporary

 
• By Natasha Barrow

Despite headwinds, executives remain optimistic about growth in Abbott’s medical devices and diabetes divisions and plan several product rollouts, including the Volt PFA catheter for electrophysiology and the dual glucose-ketone sensor CGM.

J&J Bets On Robotics, Cardiovascular To Grow Medtech As Tariff Hit Eases, US Manufacturing Grows

 
• By Shubham Singh

Worldwide medtech sales totaled $8.5bn in Q2, up 6.1%. Sales grew 8% in the US and 4.1% outside the US. Cardiovascular, surgery and vision were the primary growth drivers. Acquisitions and divestitures had net positive impact of 200 basis points, largely due to the acquisition of Shockwave Medical.